Stock Research for MACK

MACK

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

MACK Stock Chart & Research Data

The MACK chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MACK chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


MACK Due diligence Resources & Stock Charts

The MACK stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View MACK Detailed Price Forecast - CNN Money CNN View MACK Detailed Summary - Google Finance
Yahoo View MACK Detailed Summary - Yahoo! Finance Zacks View MACK Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View MACK Trends & Analysis - Trade-Ideas Barrons View MACK Major Holders - Barrons
NASDAQ View MACK Call Transcripts - NASDAQ Seeking View MACK Breaking News & Analysis - Seeking Alpha
Spotlight View MACK Annual Report - CompanySpotlight.com OTC Report View MACK OTC Short Report - OTCShortReport.com
TradeKing View MACK Fundamentals - TradeKing Charts View MACK SEC Filings - Bar Chart
WSJ View Historical Prices for MACK - The WSJ Morningstar View Performance/Total Return for MACK - Morningstar
MarketWatch View the Analyst Estimates for MACK - MarketWatch CNBC View the Earnings History for MACK - CNBC
StockMarketWatch View the MACK Earnings - StockMarketWatch MacroAxis View MACK Buy or Sell Recommendations - MacroAxis
Bullish View the MACK Bullish Patterns - American Bulls Short Pains View MACK Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View MACK Stock Mentions - StockTwits PennyStocks View MACK Stock Mentions - PennyStockTweets
Twitter View MACK Stock Mentions - Twitter Invest Hub View MACK Investment Forum News - Investor Hub
Yahoo View MACK Stock Mentions - Yahoo! Message Board Seeking Alpha View MACK Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for MACK - SECform4.com Insider Cow View Insider Transactions for MACK - Insider Cow
CNBC View MACK Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for MACK - OTC Markets
Yahoo View Insider Transactions for MACK - Yahoo! Finance NASDAQ View Institutional Holdings for MACK - NASDAQ


Stock Charts

FinViz View MACK Stock Insight & Charts - FinViz.com StockCharts View MACK Investment Charts - StockCharts.com
BarChart View MACK Stock Overview & Charts - BarChart Trading View View MACK User Generated Charts - Trading View




Latest Financial News for MACK


Merrimack Receives $225 Million Milestone Payment from Ipsen
Posted on Wednesday March 27, 2024

CAMBRIDGE, Mass., March 27, 2024--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.


Merrimack Reports Full Year 2023 Financial Results
Posted on Thursday March 07, 2024

CAMBRIDGE, Mass., March 07, 2024--Merrimack Reports Full Year 2023 Financial Results


Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the company
Posted on Monday March 04, 2024

Key Insights Significantly high institutional ownership implies Merrimack Pharmaceuticals' stock price is sensitive to...


Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Posted on Tuesday February 13, 2024

CAMBRIDGE, Mass., February 13, 2024--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") reported that Ipsen, SA ("Ipsen") issued a press release today announcing the U.S. Food and Drug Administration has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) as a first-line treatment for people living with metastatic pancreatic ductal adenocarcinoma (mPDAC).


Stock Market & Investing Books

Enter a stock symbol to view the stock details.